An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients
- 31 March 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (2-3) , 415-420
- https://doi.org/10.1016/s0959-8049(05)80065-6
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTSClinical Endocrinology, 1990
- Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedioneCancer Chemotherapy and Pharmacology, 1990
- Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancerCancer Chemotherapy and Pharmacology, 1987
- A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patientsBritish Journal of Cancer, 1985
- ENDOCRINE EFFECTS OF LOW DOSE AMINOGLUTETHIMIDE AS AN AROMATASE INHIBITOR IN THE TREATMENT OF BREAST CANCERClinical Endocrinology, 1985
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978
- The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11Endocrinology, 1977